obesity and weight management
5-HT2C selective agonists
is a selective 5-HT2C agonist with 15x more activity than on 5-HT2A receptors
, and 100x more activity than on 5-HT2B receptors
under trial for obesity management in 20102)
- appears to reduce weight by ~6kg in 1 year compared with 2kg for a placebo with almost 50% of patients losing at least 5% body weight compared with only 20% of those on placebo.
other drugs which have been tried but adverse effects generally outweigh benefits
non-selective serotonin agonists
the serotonin and noradrenaline reuptake inhibitor, sibutramine, was removed from the European market after a 100,000 patient, 6-year SCOUT study showed an increased risk of serious nonfatal cardiovascular events such as stroke or heart attack.
gastric laparoscopic banding (lap banding)
obesity.txt · Last modified: 2018/08/05 12:26 by gary1